DTx Europe: London 2023

Edouard is the Co-Founder and CEO of Tilak Healthcare, a unique video game studio creating clinically validated medical mobile games to help monitor and rehabilitate patients affected by chronic diseases.

For more than 10 years, Edouard worked in the video game industry at Gameloft, a company developing and editing mobile video games, where he successively held the positions of Project manager in Paris, then Lead Producer in New Orleans and finally managing Director of Gameloft Madrid.

Driven by his passion for innovation and technology, he was also a writer for TechCrunch France, covering mobile apps, 2.0 web and entertainment topics.

Dr Mark Jenkins is co-founder and Medical & UK Managing Director at Oviva, a NHS service provider using app-based care to transform access and outcomes in weight management for people living with type 2 diabetes and obesity.

Mark qualified from Guy’s, King’s & St Thomas School of Medicine and trained in academic nephrology (the study of kidneys) at Guy’s & St Thomas NHS Foundation Trust before working as a management consultant at the Boston Consulting Group on several NHS system transformation projects.

Today, Mark leads Oviva’s efforts supporting the NHS, overseeing our UK team of over 300 people, most of whom are clinicians including dietitians, nurses, doctors and health coaches.

Oviva is Europe’s leading provider of digitally-enabled behaviour change services, having treated over 300,000 patients to date and operating in 36 NHS ICSs, as well as in Germany, Switzerland, and France.

After a medical apprenticeship and studies in medical technology, I worked as a scientific
employee at the Federal Institute for Drugs and Medical Devices for more than seven years.
Among others, in the areas of approval of clinical trials with medical devices and vigilance.
The last two years were spent in the field of digital health applications (DiGA) as deputy
head of the according unit. In this area, I was intensively involved in the development of the
German DiGA fast-track and helped to design it. Since January 22, I have been in charge of
market access at Sympatient and now dedicate myself to solving the worldwide anxiety
crisis.

Kate is a Senior Principal based in London and is part of the Integrated Digital Health
COE. She has over 13 years of consulting experience in the US and Europe, working
with a broad range of pharmaceutical, biotechnology, diagnostic, and digital health
clients. Kate has expertise in market access strategy, launch pricing, companion
diagnostics, and commercial strategy in digital health. Kate holds a B.A. from
Princeton University in Molecular Biology

Dr Rayna Patel is a medical doctor & neuroscientist with an MPhil in Translational Medicine. She has extensive experience in academia (Cambridge, Harvard, MIT, Columbia) and was an Associate Fellow of Clare Hall College, Cambridge. Rayna has subsequently held strategic & commercial roles in government policy, tech startups & the Cabinet Office’s Nudge Unit, where she used behavioural science to rewire patient behaviours through digital products.
She is currently CEO and Co-Founder of Vinehealth, a digital platform using a combination of behavioural science and AI to improve the quality of life and survival of cancer patients, whilst generating crucial real-world data to better inform healthcare delivery and drug development.

As co-founder and managing director Christian is in charge of sales, market access, and reimbursement for Sympatient – the first digital anxiety clinic. He has a strong passion for solving complex problems in healthcare systems to ultimately enable better access to care for patients. Christian holds a degree in economics from Jacobs University, an MPhil from the University of Cambridge, and has been a visiting student at Harvard University.

Oliver is an Associate Principal based in Germany and is part of the Integrated Digital
Health COE. He has spent over 10 years driving digital health initiatives across the
UK’s National Health System – leading teams focused on the deployment of AI digital
triage solutions, remote monitoring, virtual wards and population health analytics. He
has recently worked with global life science organisations, supporting their digital
health strategies and helping them to access Germany’s DTx prescription approach –
‘DiGA’. He holds a BSc. Genetics and an MSc. Health Informatics from University
College London.

Yury Rozenman is the SVP of Pharmaceutical and Life Sciences at Propeller. In this role, he leads the company’s strategy, vision and oversees execution of all global business development activities. Prior to joining Propeller, Yury was the head of healthcare and life sciences industry partnerships at AWS where he was responsible for the development of life sciences vertical solutions, marketing programs, joint GTM strategy and execution on the global basis. Yury has 30 years of experience within the industry in pharmaceutical research and development both as a team leader and group research manager. He has worked in diagnostics and medical devices, and has been involved in the development and launch of world-class drugs and diagnostic tests.

Arvind joined atai Life Sciences in 2021 as Vice President, Digital Strategy and Operations, and is responsible for establishing and implementing atai’s Digital Therapeutics and Precision Psychiatry strategy. Prior to joining atai, Arvind was the Chief Operating Officer of Oxford VR, where he was responsible for Operations, Strategy, and Business Development. Oxford VR received Breakthrough Device designation from the FDA for the treatment of serious mental illnesses and was acquired by US operator BehaVR in 2022.

Before joining Oxford VR, Arvind was an Investment Manager at Epiris Private Equity (“Epiris”), where he was responsible for the buy-out, management, and digital transformation of companies between £100m – £500m in valuation. At Epiris, Arvind deployed and exited over £400m and £200m of capital respectively and sat on 9 Executive Boards. Arvind started his professional career at NM Rothschild & Sons where he was Vice President, Healthcare Mergers & Acquisitions.

Arvind holds a Bachelor’s and Master’s degree in Molecular and Cellular Biochemistry from the University of Oxford with dissertations in Cell Cycle Replication (Professor Kearsey) and Vaccinology (Dame Professor Gilbert).

Ryan is Managing Partner at MassMutual Ventures (MMV), leading investments across Europe and Asia-Pacific. He has over 20 years of experience as an investor, operator and board member, working with companies from seed to IPO and beyond. Ryan started his career in public markets. He was formerly an Executive Director at Goldman Sachs, and a Principal at a multi-strategy hedge fund. As an operator, Ryan has worked on strategy, product, business development, international expansion and fundraising. Ryan holds a BSc in Computer Science and an MSc in Psychology, with post-graduate research experience in Cognitive Neuroscience.